Exceptional Results from Validation Study for EchoSolv HF
Filed with ASX · · 3 pages · English
Summary by 6ix AI
EchoIQ Limited has completed a validation study for its heart failure detection software, EchoSolv HF, at the Mayo Clinic, achieving exceptional results in performance metrics. The study demonstrated a high sensitivity and specificity in detecting heart failure, exceeding the company's expectations. This completion marks the final clinical requirement before the company submits for FDA clearance, which is anticipated soon. The company plans to leverage its presence in the US market to promote EchoSolv HF following potential FDA approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from EchoIQ
- Echo IQ to Participate in the Piper Sandler 37th Annual Healthcare Conference
- Echo IQ Highlights Market Potential for EchoSolv AS Following Presentation of New Data for Severe Aortic Stenosis (AS) Presented at AHA Scientific Sessions 2025
- Quarterly Activities and Appendix 4C Cash Flow Report
- Category III CPT code application update
- Trading Halt
Later from EchoIQ
- Validation study for EchoSolv HF completed at the Mayo Clinic – Study delivers exceptional results
- Echo IQ to Present at the Life Sciences Virtual Investor Forum on 11th December
- Formal lodgement of FDA submission for EchoSolv HF
- Response to ASX Price Query
- Quarterly Activities Report and Appendix 4C Cash Flow Report
Follow EchoIQ into a list and get an email when it puts out news.
Follow EchoIQ